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Background: Retrospective studies based on clinical data and without spirometric confirmation 
suggest a poorer prognosis of patients with ischemic heart disease (IHD) and chronic obstructive 
pulmonary disease (COPD) following percutaneous coronary intervention (PCI). The impact of 
undiagnosed COPD in these patients is unknown. We aimed to evaluate the prognostic impact 
of COPD – previously or newly diagnosed – in patients with IHD treated with PCI.
Methods: Patients with IHD confirmed by PCI were consecutively included. After PCI they 
underwent forced spirometry and evaluation for cardiovascular risk factors. All-cause mortality, 
new cardiovascular events, and their combined endpoint were analyzed.
Results: A total of 133 patients (78%) male, with a mean (SD) age of 63 (10.12) years were 
included. Of these, 33 (24.8%) met the spirometric criteria for COPD, of whom 81.8% were 
undiagnosed. IHD patients with COPD were older, had more coronary vessels affected, and a 
greater history of previous myocardial infarction. Median follow-up was 934 days (interquartile 
range [25%–75%]: 546–1,160). COPD patients had greater mortality (P=0.008; hazard ratio 
[HR]: 8.85; 95% confidence interval [CI]: 1.76–44.47) and number of cardiovascular events 
(P=0.024; HR: 1.87; 95% CI: 1.04–3.33), even those without a previous diagnosis of COPD 
(P=0.01; HR: 1.78; 95% CI: 1.12–2.83). These differences remained after adjustment for sex, 
age, number of coronary vessels affected, and previous myocardial infarction (P=0.025; HR: 
1.83; 95% CI: 1.08–3.1).
Conclusion: Prevalence and underdiagnosis of COPD in patients with IHD who undergo PCI 
are both high. These patients have an independent greater mortality and a higher number of 
cardiovascular events during follow-up.
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Background
Ischemic heart disease (IHD) and chronic obstructive pulmonary disease (COPD) are 
within the top causes of mortality worldwide.1 The prevalence of IHD is considered 
increased in patients with COPD and is one of the most frequent causes of death across 
the entire spectrum of COPD severity.2 Nevertheless, the inverse situation – that is, 
a greater prevalence of COPD and a worse prognosis in IHD patients – has been less 
studied.
In the past decade, only retrospective studies have indicated that COPD worsens 
the prognosis of patients with IHD. For example, Berger et al found greater mortality 
in patients with a previous diagnosis of COPD and IHD who underwent percutaneous 
coronary intervention (PCI);3 these data were corroborated in subsequent studies.4,5 
Prior diagnosis of COPD has also been related to a greater number of complications 
and increased mortality in patients with acute myocardial infarction.6–12
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As mentioned, all these studies were retrospective and 
the diagnosis of COPD was based on clinical history only, 
without spirometric confirmation, which likely led to an evi-
dent underdiagnosis; this explains in part why the prevalence 
of COPD in these studies is often less than that found in the 
general population.13,14
To our knowledge only one previous study – based in 
119 patients – has examined the real prevalence of COPD 
in patients with IHD as demonstrated with PCI by means of 
spirometry, revealing a COPD prevalence of 34%, of which 
87% were not previously diagnosed.15
We aimed to evaluate whether patients with IHD, demon-
strated by PCI, along with COPD confirmed by spirometry – 
with or without previous diagnosis – had a worse prognosis 
in terms of mortality and increased number of cardiovascular 
events than patients with IHD alone.
Methods
All patients admitted at the hemodynamic unit of the Mutua 
de Terrassa University Hospital due to IHD who underwent 
a PCI revealing stenosis above 50% in primary arteries, from 
January to June 2011, and gave their informed consent, were 
included. Patients with significant valvulopathy, persistent 
signs of heart failure, unable to carry out spirometry, and 
those diagnosed with asthma or bronchiectasis as the main 
respiratory disease were excluded. Data collected included 
the characteristics of the PCI, number of arteries affected 
and treated, stents implanted, and postprocedural flow. At 
the time of the PCI, the logistic EuroSCORE was calculated, 
the prognostic evaluation according to the GRACE scale was 
also recorded and the SYNTAX and ACA/AHA (American 
College of Cardiology/American Heart Association) coro-
nary lesion complexity indices were analyzed.16–21 Analytical 
variables were drawn at the time of the PCI.
One month after PCI, a postbronchodilator spirometry 
was performed according to international guidelines, and 
reviewed by an experienced pulmonologist (JLLH).22 We 
used a standardized questionnaire to assess the previous 
diagnosis of COPD.15,23 Other cardiovascular and COPD risk 
factors alongside other comorbidities, both included or not 
in the Charlson index, were recorded.24 COPD was defined 
as a post-bronchodilator forced expiratory volume in the 1st 
second (FEV
1
)/forced vital capacity (FVC) ratio ,0.70. Spiro-
metric severity was stratified in accordance with the Global 
initiative for chronic Obstructive Lung Disease (GOLD) 
normative.25 The lower limit of normality (LLN) was also 
calculated, using the Global Lung Function Initiative software 
(http://www.lungfunction.org). The patients’ regular physicians 
were informed of their spirometric data, without posterior 
intervention on the part of the researchers in their medication 
or additional tests performed on the patients. Follow-up was 
carried out based upon the information contained in the clinical 
record and by means of telephone contact. Data and cause of 
death were collected, as was information on admissions for 
cardiovascular or respiratory reasons. A combined mortality/
major cardiovascular event (MACE) variable including death 
or hospital admission for a new acute coronary syndrome, heart 
failure, or cerebral vascular event, was calculated. A study 
based on the number of MACE events was also performed. 
The relationship between predicted FEV
1
%, predicted FVC%, 
and FEV
1
/FVC, expressed as a continuous variable stratified 
for events, was also examined.
statistical analysis
Data are presented as means and standard deviation (SD) 
for continuous variables, or as totals and percentages for 
qualitative variables. Differences within groups were com-
pared with Student’s t-test or non-parametric tests and the 
chi-squared test for continuous and categorical variables, 
respectively. Time-dependent variables were analyzed with 
Kaplan–Meier curves and Cox logistic regression analysis. 
Statistical significance was determined for P-values below 
0.05. All patients signed their informed consent. The study 
was approved by the ethical and clinical trial committee of 
the Mutua de Terrassa University Hospital.
Results
A total of 171 patients were initially studied, of whom 38 
were then excluded. Excluded patients were older: 63 (10.12) 
vs 67.64 (12.42) years (P=0.022), although there were no 
differences in terms of sex, history of cardiovascular risk, or 
number of treated arteries. Finally, 133 patients were included 
(78.2% males) with a global mean (SD) age of 63.03 (10.12) 
years and 33 (24.8%) met the spirometric criteria for COPD. 
Ten patients had mild COPD (30.3%), 19 moderate COPD 
(57.6%), and four severe COPD (12.1%). The global preva-
lence of underdiagnosis was 81.8%. All of the severe COPD 
patients had been previously diagnosed, while underdiagnosis 
in patients with moderate and mild COPD was 89.5% and 
100%, respectively (Figure 1).
The main characteristics of the participants in the presence 
or not of COPD are presented in Table 1. Patients with COPD 
were significantly older and had a more frequently history of 
previous myocardial infarction, while the Charlson index was 
similar between groups. Previous use of antiplatelets and statins, 
and other indicators of cardiovascular risk, was not significantly 
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different. Findings obtained in the PCI are shown in Table 2. 
COPD patients had a greater number of affected coronary 
arteries, although there were no differences in the number of 
arteries or lesions treated, the percentage of patients achieving 
total revascularization, the number of stents implanted – drug-
eluting or otherwise – or the ejection fraction (Table 2).
In accordance with the ACC/AHA classification, 7% had 
type a lesions, 60% type b, and 33% type c, with no difference 
between the COPD patients and the rest; similarly scoring 
was similar for those with and those without COPD on the 
Syntax index in grouping those at low risk (0–22), medium 
risk (23–32), and high risk ($33).
Analytic parameters were likewise comparable. Those 
patients with COPD had lower total cholesterol levels 
although this difference disappeared when subjects with a 
prior diagnosis of dyslipidemia or under treatment with statins 
were analyzed (Table 3). We did not find differences between 
patients with and without COPD at the time of discharge after 
Figure 1 Flowchart of patients.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in the 1st second; FVC, forced vital capacity.
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Table 1 Demographic and clinical characteristics of participants according to spirometry FeV1/FVC ,0.70
COPD (n=33) Non-COPD (n=100) Total (n=133) P-value
Male sex (n) (%) 28 (84.8) 76 (76) 78.2% ns
age, years (sD) 67.48 (9.91) 61.56 (9.79) 63.03 (10.1) 0.003
BMI (kg/m2) 28.91 (5.43) 31.3 (14.74) 30.71 (13.01) ns
smoking ns
Current 6 (18.2%) 17 (17%) 23 (17.3%)
ex-smoker 21 (63.65%) 57 (57%) 78 (58.6%)
Pack-years 35.23 (20.63) 27.79 (25.62) 29.82 (24.5) ns
Charlson’s index 1.87 (1.49) 1.48 (1.26) 1.57 (1.32) ns
Waist circumference 100.77 (10.57) 103.71 (9.68) 103 (9.94) ns
Dyslipidemiaa 22 (66.7%) 62 (62%) 84 (63.2%) ns
Peripheral vasculopathya 3 (9.1%) 5 (5%) 8 (6%) ns
hypertensiona 23 (69.7%) 100 (69%) 92 (69.2%) ns
Diabetes mellitusa 12 (36.4%) 27 (27%) 39 (29.3%) ns
heart failurea 6 (18.2%) 9 (9%) 15 (11.3) ns
strokea 3 (9.1%) 3 (3%) 6 (4.5%) ns
aMIa 14 (42.4%) 24 (24%) 38 (28.6%) 0.03
anginaa 22 (66.7%) 54 (54%) 76 (57.1%) ns
Cardiac surgerya 8 (24.2%) 21 (21%) 29 (21.8%) ns
Previous use statins 17 (51.5%) 65 (65%) 82 (61.7%) ns
Previous use antiplatelets 18 (54.5%) 60 (60%) 78 (58.6%) ns
Depression: Yesavage scale, mean (sD) 3.82 (2.82) 4.05 (3.8) 3.99 (3.56) ns
Notes: aPrevious diagnosis of dyslipidemia, arterial peripheral vasculopathy, diabetes mellitus, hypertension, heart failure, stroke, acute myocardial infarction (aMI), angina 
or cardiac surgery.
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in the 1st second; FVC, forced vital capacity; ns, 
non-significant; SD, standard deviation.
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PCI or during follow-up in the prescription of antiplatelets, 
statins, beta-blockers, angiotensin-converting-enzyme (ACE) 
inhibitors, angiotensin II inhibitors, or calcium antagonists 
(Figure 2). There were, however, differences in the use of 
bronchodilators and inhaled corticosteroids, both more fre-
quent among the patients with COPD (P,0.001).
The median follow-up period was 974 (interquartile 
range: 546–1,160) days. During follow-up eight deaths 
occurred, six in the COPD group (18.2%) and two in the non-
COPD group (2%) (P=0.003). There were 88 new events, of 
which 35 were in the COPD group and 53 in the non-COPD 
group (P=0.015), as well as a greater number of events per 
patient: 1.36 (0.29) vs 0.63 (0.97) (P=0.02).
When analyzing survival and MACE using a Cox 
regression model, COPD patients showed a worse progno-
sis with regard to mortality (P=0.008; hazard ratio [HR]: 
8.85; 95% confidence interval [CI]: 1.76–44.47) and to the 
MACE variable (P=0.024; HR: 1.87; 95% CI: 1.04–3.33). 
These differences were sustained when the total number of 
events in the MACE variable was examined in relation to 
whether or not the patient had COPD (P=0.003; HR: 1.84; 
95% CI: 1.14–2.74) (Figure 3). COPD patients without a 
prior diagnosis also showed a worse prognosis with the 
MACE variable (P=0.001; HR: 1.78; 95% CI: 1.12–2.83) 
(Figure 4A). The significance of COPD was maintained after 
adjusting for age, sex, previous myocardial infarction, and 
number of arteries affected (Table 4 and Figure 5).
When classifying the COPD patients in terms of LLN 
the prevalence observed went down to 15 patients (11.3%), 
five with mild COPD, six with moderate, and four with 
severe, thereby reducing the underdiagnosis to 67%. In 
terms of LLN, no differences in mortality were found, 
although statistical significance was maintained for the 
MACE variable (P=0.03; HR: 2.26; 95% CI: 1.1–4.68) 
and for the total number of events in the non-adjusted 
analysis (P=0.002; HR: 2.37; 95% CI: 1.48–3.83). How-
ever, this significance disappeared in the multivariate 
model (Table 4 and Figure 5). The number of arteries 
with stenosis maintained its statistical significance in both 
multivariate models.
Subjects with discordant results (obstructive by fixed 
ratio but normal by LLN) had a greater number of events 
than patients without COPD and a smaller number than the 
patients meeting both criteria (P,0.002). Total number 
Table 2 Characteristics of the PCI, according to spirometry FeV1/FVC ,0.70
COPD (n=33) Non-COPD (n=100) Total (n=133) P-value
graCe score at hospital (sD)18 16.36 (26.96) 10.23 (5.44) 14.4 ns
graCe score at 6 months (sD)18 25.21 (21.18) 19.8 (8.43) 21.20 (12.96) ns
logistical eurosCOre (median and IQr)17 11 (6–15) 2 (2–3.8) 3 (2–10) 0.006
sYnTaX (sD)19 13.77 (10.81) 13.09 (10.42) 13.25 (10.46) ns
number of arteries affected (sD) 1.91 (0.84) 1.56 (0.7) 1.64 (0.75) 0.04
number of arteries treated (sD) 1.3 (0.47) 1.23 (0.48) 1.25 (0.47) ns
number of lesions treated (sD) 1.47 (0.67) 1.44 (0.69) 1.45 (0.68) ns
number of stents (sD) 1.47 (0.69) 1.4 (0.66) 1.42 (0.67) ns
number of drug-eluting stents (sD) 1.21 (0.92) 0.96 (0.89) 1.01 (0.89) ns
ejection fraction (sD) 56.67 (13.26) 60.20 (13.31) 59.26 (13.32) ns
Complete revascularization (%) 10 (30.3%) 46 (46%) 56 (42.1%) ns
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in the 1st second; FVC, forced vital capacity; IQr, interquartile range 
(25%–75%); PCI, percutaneous coronary intervention; sD, standard deviation.
Table 3 Blood analysis of participants according to spirometry FeV1/FVC ,0.70
COPD (n=33) Non-COPD (n=100) Total (n=133) P-value
Total cholesterol (mg/dl) 161.33 (46.29) 182.86 (42.92) 177.24 (44.64) 0.02
hDl cholesterol (mg/dl) 45.46 (12.97) 45.98 (11.98) 45.85 (12.182) ns
lDl cholesterol (mg/dl) 90 (32.59) 106.35 (39.78) 102.41 (38.66) ns
Triglycerides (mg/dl) 105.69 (92.46) 134.29 (73.26) 127.02 (79.14) ns
CrP 2 (5.45) 0.87 (2.1) 1.13 (3.21) ns
BnP (pg/ml) 1,839 (4,137) 832 (2,437) 1,092 (2,984) ns
Total cholesterola (mg/dl) 167 (40.37) 181 (43.95) 177 (43.2) ns
hDl cholesterola (mg/dl) 46.24 (11.25) 44.68 (11.65) 45.1 (11.5) ns
lDl cholesterola (mg/dl) 96.82 (31.8) 102.9 (41.2) 101.49 (38.99) ns
Note: aTotal cholesterol levels and fractions in patients with previously prescribed statins. Data are presented as mean  (standard deviation).
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced expiratory volume in the 1st second; FVC, forced vital capacity. BnP, brain natriuretic peptide; 
CRP, c-reactive protein; HDL, high density lipoprotein; LDL, low density lipoprotein; ns, non-significant.
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of events with Cox regression in the discordant patients 
were similar to those with the COPD according to the 
fixed ratio.
The relationship within percent predicted FVC, FEV
1
, 
and FEV
1
/FVC with the number of stratified events was a 
statistically significant inverse one (Figure 6). Finally when 
using both the fixed ratio and the lower limit for normality 
in defining obstruction, the number of events increased with 
the severity of COPD (both P,0.0001) (Figure 4B).
Discussion
Our study demonstrates high rates of prevalence (25%) 
and underdiagnosis (82%) of COPD in patients with IHD 
leading to PCI, as well as lower survival and a greater 
number of cardiovascular events in patients with COPD, 
including those who were not previously diagnosed. To our 
knowledge, this is the first study in which this prognostic 
relationship has been demonstrated conjointly using the two 
techniques considered as GOLD standards: PCI in IHD and 
spirometry in COPD.
It is well established that COPD is associated with IHD 
even after adjustment for confounding variables, and that the 
presence of IHD worsens the prognosis in COPD.26–30 The 
inverse situation – an increase in the risk of COPD in patients 
with a history of cardiovascular disease – has been shown in 
other studies.14,31,32 The worsened prognosis for patients with 
IHD and COPD together has been demonstrated in various 
studies carried out in patients with IHD who have undergone 
PCI.3–5,9,11,12 Other studies have shown a worse prognosis 
for patients with COPD and acute myocardial infarction, 
revealing greater risk of heart failure, bleeding, cardiogenic 
shock, and mortality.6–8,10 Unfortunately, none of these studies 
included a systematic use of spirometry to confirm or rule out 
the diagnosis of COPD. Rather, they were based solely on a 
prior diagnosis of COPD in the patient’s clinical record or 
the previous use of bronchodilators, which likely produced 
a bias and an evident underdiagnosis. Recent studies have 
shown that, although the specificity of the prior diagnosis 
of COPD in patients with IHD is high, previous diagnosis 
sensitivity is very low (23%), with a positive predictive value 
of 53%.33 In our study, the prevalence of underdiagnosis was 
similar to what was seen in a previous study.15
Our data demonstrate that both mortality and the number 
of events of patients with COPD – with or without previous 
diagnosis – and concomitant IHD were greater than in IHD 
patients without COPD. COPD patients were similar to the 
others except for their more advanced age, a higher number 
Figure 2 Treatment at discharge and during patient follow-up.
Abbreviations: aCe, angiotensin converting enzyme inhibitors; araII, angiotensin II receptor antagonist; COPD, chronic obstructive pulmonary disease; PCI, percutaneous 
coronary intervention.
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Figure 3 Kaplan–Meier survival curves for the mortality/major cardiovascular event 
variable (MaCe).
Abbreviation: COPD, chronic obstructive pulmonary disease.
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of previous incidents of infarction, and a greater number 
of stenosed arteries. Several previous retrospective studies 
have also found a greater prevalence of prior infarction in 
patients with COPD, although data concerning the number 
of stenosed arteries, the complexity of the coronary lesions, 
and the procedures for revascularization in these studies 
were variable.3–5,9,11 Nevertheless, the rest of the parameters 
analyzed in our study, including the GRACE risk and the 
Syntax and ACC/AHA coronary complexity scales, were 
similar. Only the logistic EuroSCORE was higher in COPD 
patients, although this difference may be explained by the 
older age and prior diagnosis of COPD in some patients, 
variables that are included in this index.
The number of arteries with stenosis was related to a 
higher number of events during follow-up, in both the crude 
and the adjusted analysis, which is in agreement with other 
studies.34 However, the number of arteries treated and the 
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Figure 4 Kaplan–Meier curves for (A) Patients without prior diagnosis of COPD. (B) Total number of events by gOlD stage.
Abbreviations: COPD, chronic obstructive pulmonary disease; gOlD, global initiative for chronic Obstructive lung Disease; MaCe, mortality/major cardiovascular event 
variable.
Table 4 Multivariate analysis by event using Cox regression
HR 95% CI P-value
COPD fixed ratio
COPD 1.83 1.08–3.1 0.025
sex 1.1 0.62–1.99 ns
age 1.01 0.98–1.03 ns
aMIa 1.16 0.68–1.98 ns
number of stenosed arteries 1.45 1.08–3.11 0.03
COPD lower limit of normality
COPD 1.47 0.77–2.81 ns
sex 1.18 0.66–2.13 ns
age 1.01 0.99–1.04 ns
aMIa 1.27 0.74–2.18 ns
number of stenosed arteries 1.45 1.01–2.1 0.046
Note: ahistory of previous acute myocardial infarction (aMI).
Abbreviations: AMI, acute myocardial infarction; CI, confidence interval; COPD, 
chronic obstructive pulmonary disease; HR, hazard ratio; ns, non-significant.
number of stents implanted were somewhat greater in those 
patients with COPD, albeit short of statistical significance, 
which suggests that the worse prognosis of COPD patients is 
not attributable to lessened treatment during the PCI of other 
arteries with stenosis not responsible for the current coro-
nary event. Recent studies have shown that non-treatment 
of these arteries is associated with a poor prognosis during 
follow-up.35
The causes of this worse prognosis for patients with IHD 
and COPD are not entirely clear. Some population-based 
studies have pointed to poorer adherence to treatment guide-
lines for IHD in patients with COPD, with less use of statins 
and beta-blockers, but this was not confirmed in our study, 
in which the treatment at discharge following PCI and the 
follow-up with statins, antiplatelets, beta-blockers, calcium 
antagonists, and ACE inhibitors were comparable.36,37 Other 
possible explanations might include a greater arterial stiff-
ness and higher platelet aggregation and inflammation, all of 
which are aggravated during COPD exacerbations, with an 
increased incidence of cardiovascular events in the following 
weeks after COPD exacerbation.29,38–41 This increase in plate-
let aggregation in COPD patients has also been demonstrated 
in patients with IHD leading to PCI.42
Finally, in our study the use of LLN reduced the level of 
underdiagnosis but also excluded a sub-group of patients with 
a greater number of cardiovascular events and their relation-
ship with the number of events in the multivariate model was 
not significant. These data had already been suggested by 
other studies that demonstrated an increase in the mortality 
due to IHD with the reduction of pulmonary function, and 
higher mortality in those patients classified as non-COPD by 
LLN but with obstruction criteria from the fixed ratio.43,44
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Figure 5 Hazard ratio and 95% CI for COPD by the fixed ratio and the LLN index both raw and adjusted by sex, age, number of arteries with stenosis, and history of AMI.
Abbreviations: AMI, acute myocardial infarction; COPD, chronic obstructive pulmonary disease; LLN, lower limit of normality; CI, confidence interval.
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Figure 6 relationship between number of events (MaCe) and percent predicted FVC, FeV1, and FeV1/FVC.
Abbreviations: CI, confidence interval; MACE, combined mortality/major cardiovascular event; FEV1, forced expiratory volume in the 1st second; FVC, forced vital 
capacity.
Our study has some limitations. Only IHD patients who 
underwent PCI were included, so that our conclusions may 
not be generalized to all patients with IHD; in all likelihood, 
the oldest patients and those with the most comorbidities were 
not included as they were not referred for PCI. Although the 
average age observed in our study was similar to the age in 
the other studies carried out among PCI patients, it is lower 
than the overall age for patients with IHD.5,11,45 Secondly, 
by being a single center study we maximize internal consis-
tency in procedures and treatments, but the limited size of 
the sample may mean that some of the differences observed 
in the characteristics of patients failed to reach statistical 
significance. Finally, some classic studies have suggested 
that myocardial infarction may transiently affect respiratory 
function, although the FEV
1
/FVC is usually less affected.46 
In our study, spirometry was performed 1 month after the 
PCI and recent publications demonstrate that after an acute 
coronary syndrome treated with PCI, spirometric values 
performed at this time are similar to those observed during 
follow-up.47
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Conclusion
Despite these limitations, we believe that our study demon-
strates the poorer prognosis of patients with COPD – with or 
without previous diagnosis – both in terms of mortality and 
in cardiovascular events during follow-up independently of 
other variables, which highlights the need to carry out spiro-
metric studies in order to detect COPD in IHD patients for 
their prognostic and possibly therapeutic implications.48
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